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Cyclosporin A (CsA) has proven effective as an inhibitor of a variety of T cell
responses in vitro, including antigen-specific proliferation, macrophage-mediated
antigen presentation, and antigen- and lectin-induced cytokine production, in-
cluding IL-1, IL-2, IL-3, and IFN-y, but not IFN-a/# (1). CsA appears to function
in the prevention of graft rejection by affecting the early activation of immuno-
competent cells, possibly by blocking antigen-specific receptor binding, class I
and II expression, inhibition of phospholipase A2 activity, and/or inhibition of
synthesis of cytokine mRNA (1-4). The selective suppressive activity of CsA for
cell-mediated immunity prompted its use in human organ transplantation (5).
Transforming growth factors (TGFs) are a family of peptides that, under
certain conditions, can induce normal cells to express a transformed phenotype
(6). At least two types of TGFs have been described: TGF-a, which is homologous
to epidermal growth factor (EGF), and TGF-f3. Mature TGF-a is a 25 kD
homodimer held together by disulfide bonds that binds to a specific receptor(s)
distinct from the TGF-a or EGF receptor (6). TGF-0 inhibits IL-2-induced T
cell proliferation, IL-2-R induction, IL-1-induced thymocyte proliferation, IFN-
a but not IL-2-induced NK activity, B cell proliferation to growth factors and
IFN-y-induced class II antigen expression on Hs294T melanoma cells (7-11).
In this report, we describe the effects of CsA and TGF-(3 on the production of
TNF-a (also referred to as cachectin), TNF-# (lymphotoxin), and IFN-y by
human PBMC and murine peritoneal macrophages. Our results demonstrate
that CsA and TGF-0 have suppressive effects on cytokine production that are
dependent on their selective activity on specific cell types.
Materials and Methods
Cytokines. Recombinant human IFN-y (rHuIFN-,y) and murine IFN-,y (rMuIFN-y),
cloned and expressed in Escherichia coli (12, 13), were purified to >99% purity ~Rinder-
knecht, E., unpublished results). Specific activity of both IFNs was 1-2 x 10 U/mg
protein.
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Isolation and Treatment of Mononuclear Cell Populations.
￿
PBMC were isolated from
buffy coats (Peninsula Blood Bank, Burlingame, CA) by Ficoll-Hypaque density sedimen-
tation. The purified PBMC (2 X 106 cells/ml) were seeded into 24-well tissue culture
plates (Costar, Cambridge, MA) in RPMI 1640 medium supplemented with 10% heat-
inactivated FCS (HyClone Laboratories, Logan, UT), 100 U/ml penicillin, and 100 ug/ml
streptomycin (Gibco Laboratories, Grand Island, NY) (CRPMI). PBMC were pretreated
with various doses of porcine platelet-derived TGF-# (>97% pure, R and D Systems Inc.,
Minneapolis, MN) for different time periods at 37°C, after which PHA-P (Difco Labora-
tories Inc., Detroit, MI) was added at a final concentration of 20 cog/ml. CsA (Sandoz,
East Hanover, NJ) was added at various doses either simultaneously or 20 h before
addition of 20 ug/ml PHA-P.
Adherent human monocytes were isolated by seeding PBMC into 24-well tissue culture
plates (4 X 106 cells/well) and incubated for 90 min at 37 ° C. Nonadherent cells were
removed and the adherent cells were washed three times in RPMI 1640 medium before
addition of CRPMI. After 20 h of incubation with various concentrations of TGF-,B, 1 Ag
LPS/ml (E. coli LPS 026:116, Sigma Chemical Co., St. Louis, MO) and 1,000 U/ml
rHuIFN-y were added. Supernatants were removed for TNF-a ELISA assay 4 h later.
Murine peritoneal macrophages were obtained from 6-8-wk-old female BALB/c mice
(Charles River Breeding Laboratories, Wilmington, MA). Peritoneal exudate cells (PEC)
obtained from mice injected intraperitoneally 5-7 days previously with 0.5 ml thioglyco-
late (Difco Laboratories Inc.) were resuspended in DMEM supplemented with 10% heat-
inactivated FCS, 2 MM L-glutamine, 100 U/ml penicillin, and 100 ug/ml streptomycin
and were incubated in plastic petri dishes for 1 h at 37'C. The adherent macrophages
were scraped off gently and added to 12-well tissue culture plates (Costar) at 5 X 105/well
with various concentrations of TGF-S. After4 h of incubation with TGF-,B, 5 ug/ml LPS
and 100 U/ml rMuIFN-y were added. Supernatants were removed after 72 h and were
assayed for murine TNF-a activity in the L-M bioassay (14).
Cytokine Assays.
￿
Human TNF-a and IFN-y levels were determined by specific ELISA
assays: The TNF-a ELISA has a detection limit of 40 pg/ml and the IFN-y ELISA 0.4
ng/ml (15, 16). Human TNF-# and murine TNF-a were assayed on the L-M bioassay
with a detection limitof 4 U/ml (14). To determine the levelof TNF-0, all TNF-a activity
was first neutralized by adding a threefold excess of a rabbit polyclonal anti-TNF-a
antibody (17) for at least 30 min before assay. This antiserum has a neutralizing titer of
2 .9 X 104 L-M U/,l . In the L-M bioassay, rHu TNF-# has a specific activity of 2 X 108
U/mg protein, and rHuTNF-a, 4 X 10' U/mg protein.
Results
Effects of CsA and TGF-0 on Cytokine Production.
￿
We examined the effects of
CsA and TGF-0 on TNF-a, TNF-0, and IFN--y production by various PBMC
populations. As shown in Fig. 1 A, CsA, in a dose-related manner, inhibited the
production of all three cytokines produced by PHA-P-stimulated unseparated
PBMC cultures. CsA was more effective in inhibiting TNF-,B and IFN-y produc-
tion compared with TNF-a (Fig. 1 A), although a similar level of inhibition of
TNF-a production could be obtained at a 10-fold higher CsA concentration
(data not shown) .
TGF-0 also inhibited the production of IFN-y in a dose-related manner, with
maximal inhibition observed at 10 ng/ml(Fig. 1 B). To obtain maximal inhibition
of IFN-y production, it was necessary to pretreat the PBMC for at least 4 h with
TGF-0 before the addition of PHA-P, although the addition of TGF-0 at the
initiation of culture resulted in significant inhibition (data not shown). In contrast
to the inhibitory effects of CsA, TGF-0 only minimally inhibited TNF-a and
TNF-,Q production by PHA-P-stimulated unseparated PBMC (Fig. IB). Trypan
blue exclusion analyses of untreated and either CsA- or TGF-,0-treated PBMC100
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FIGURE 1.
￿
Effects of CsA (A) and
TGF-j6 (B) on inhibition of cytokine
production by unseparated PBMC.
CsA was added together with 20
,ug/ml PHA-P. TGF-,B wasadded 4 h
before PHA-P. TNF-a (p), TNF-0
(0)and IFN-y (0) levels were deter-
mined after 72 h of incubation. Re-
sults are presented as mean percent
inhibition tSEM (n = 6 forA and 5
for B). Mean cytokine production
from untreated cultures was 1,431
pg/ml for TNF-a, 417 U/ml for
TNF-fl, and 21 ng/ml for IFN-y.
cultures demonstrated similar cell viabilities (data not shown), suggesting that
the inhibitory effects were not mediated bya reduction in cell viability but rather
a suppression of functional abilities.
It was also demonstrated that anti-CD3 antibodies enhanced TNF-a and IFN-
ti production by unseparated PBMC, and in support of the data with PHA-P
stimulation, TGF-0 significantly inhibited IFN-1' but not TNF-a production in
the anti-CD3-stimulated cultures (data not shown). Since TNF-a is produced by
various lymphoid populations (17, 18), wecomparedthe ability ofCsAand TGF-
# to regulate TNF-a production by adherent, nonadherent, and unseparated
PBMC cultures. TNF-a production by nonadherent PBMC was more susceptible
to inhibition by CsA as compared with adherent PBMC and that thenonadherent
cells (which contain both NK and Tcells) produce TNF-a (Table I). In contrast,
TGF-# inhibited TNF-a production by adherent PBMC over a range ofconcen-
trations tested (0.1-10 ng/ml), whereas TNF-a production by the unseparated
PBMC was not significantly inhibited even at the highest concentration. In
addition, TGF-# significantly enhanced TNF-a production at 1.0 and 0.1 ng/ml.
A similar enhancement ofTNF-a production by unseparated PBMC at subnan-
ogram concentration ofTGF-# was observed in 8 of 15 donors tested (data not
shown).
The finding that TGF-# inhibited TNF-a production by human monocytes
was further confirmed in murine macrophages (Table I), indicating that TNF-a
production by monocytes/macrophages is particularly sensitive to the inhibitory
effects of TGF-# and that the immunoregulatory activities of TGF-l0 are not
species specific. Moreover, TGF-,B significantly inhibited macrophage-mediated
tumor cell cytostasis/cytotoxicity ofNIH-3T3 target cells (data not shown).
Discussion
CsA, a widely used immunosuppressive agent, is a potent inhibitor ofIL-1, IL-
2, IFN-y, and IL-3, as well as TNF-a and TNF-fl production by human PBMC
cultures (1-4). TNF-a has now been shown to exert a variety of immunoregula-
tory activities, such as stimulation of class I and class 11 antigen expression and574
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TABLE I
Comparative Effects ofTGF-0 on TNF-a Production by Various Mononuclear Cell Populations
* Nonadherent, adherent, and unseparated PBMC were pretreated for 24 h with CsA or TGF-0 before addition
of stimulus. Nonadherent and unseparated PBMC were stimulated with 20 pg/ml PHA-P for 48 h and adherent
PBMC were stimulated with 1 jug/ml LPS and 100 U/ml rHuIFN-y for 4 h before supernatants were assayed for
TNF-a levels. Murine peritoneal macrophages were pretreated for 4 h with TGF-0 before addition of 5 jug/ml
LPS and 100 U/ml rMuIFN-y for 72 h.
x Results are presented as U/ml.
IL-1 production, as well as its involvement in cytotoxic T cell generation (19-
20) (Ranges et al., unpublished observations). These results suggest that one
important mode of action of CsA as an immunosuppressive agent may also be
mediated through the inhibition of TNF-a production.
Recently, TGF-0 has also been shown (7-11) to be a potent immunosuppressive
agent in a variety of immunological systems. Our results demonstrate that TGF-
0 is a potent inhibitor of IFN-y production by PBMC cultures. TGF-,B inhibits T
cell proliferation, probably by downregulating the expression of IL-2-R (7). The
mechanism by which TGF-0 inhibits NK-mediated killing is not known, but it
has been suggested that TGF-0 may inhibit the low levels of IFN produced in
lymphocyte cultures that are important in the continuous recruitment and
activation of pre-NK cells (9). Our observation that IFN-y production by PBMC
was inhibited by TGF-0 suggests that TGF-0 may suppress immune responses by
inhibiting cytokine production.
It is unclear why TGF-0 inhibits IFN-y but not TNF-a production, both of
which are products of lymphocytes. After mitogenic stimulation of PBMC, IFN-
y production precedes the production of TNF-(3 (18). In addition, recent studies
have demonstrated that TGF-,B can inhibit cytotoxic T lymphocyte as well as
lymphokine activated killer cell development in vitro (Ranges et al . ; Espevik, T.,
et al., unpublished observations). Presumably the failure of TGF-0 to significantly
inhibit TNF-# production, a relatively late-occurring event, indicates that TGF-
0 affects early stages of lymphoid cell maturation.
Although the immunosuppressive action of CsA seems to be most pronounced
on T cells, previous studies (1) have shown that CsA can also affect macrophage
functions. TNF-a production by adherent monocyte-enriched PBMC cultures
Exp. Mononuclear cell populations* Treatment TNF-a t SE Change
pg/ml
1 PBMC (nonadherent) - 13,134 f 1,501 -
1 pg/ml CsA 1,480 ± 159 -88
PBMC (adherent) - 1,736 t 144 -
1 pg/ml CsA 1,458 ± 40 -14
10 ng/ml TGF-0 748 t 19 -57
1 ng/ml TGF-# 1,283 t 18 -26
0.1 ng/ml TGF-# 1,380 t 18 -21
PBMC (unseparated) - 4,550 t 16 -
10 ng/ml TGF-# 3,986 t 192 -12
1 ng/ml TGF-# 6,326 t 66 +40
0.1 ng/ml TGF-# 6,339 t 19 +40
2 Murine peritoneal macrophages - 253 t 33$ -
10 ng/ml TGF-S 74 t 5 -71
1 ng/ml TGF-0 100 ± 20 -60
0.1 ng/ml TGF-# 164 t 21 -35ESPEVIK ET AL.
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was less inhibited by CsA as compared with nonadherent lymphocyte-enriched
PBMC cultures. In contrast, our results demonstrate that TNF-a production by
adherent monocyte-enriched PBMC cultures was inhibited by TGF-,B to a greater
extent than in unseparated PBMC. These results suggest that TGF-,B may
primarily affect TNF-a production in monocytes, whereas CsA primarily inhibits
TNF-a production in nonadherent lymphoid cells.
The significance of the finding that TGF-,B suppresses cytokine production
may be of importance in a homeostatic mechanism acting to limit cytokine-
mediated inflammatory responses. This effect could occur through the release
of TGF-# by activated platelets and T cells (7) at sites of inflammation and result
in a reduction of immune cell cytokine production, class II antigen expression,
and cytotoxic T cell development.
Summary
We investigated the ability of cyclosporin A (CsA) and transforming growth
factor ,B (TGF-#) to modulate the production of TNF-a and TNF-,B and IFN-y
by unseparated, nonadherent, and adherent PBMC. Treatment of unseparated
PBMC with CsA resulted in a significant dose-dependent inhibition of all three
cytokines ranging from >90% inhibition for IFN-y and TNF-,B, to ^-70% for
TNF-a. Pretreatment of unseparated or nonadherent PBMC with TGF-# inhib-
ited the production of IFN-y by 60-70% . However, the inhibition of TNF-a
and TNF-,Q production by these cells was only minimally affected, and at 0 .1-1
ng/ml TGF-# could enhance TNF-a production by unseparated PBMC. In
contrast, pretreatment of adherent PBMC with TGF-# inhibited the production
of TNF-a by ^-60%. TGF-,B also inhibited both TNF-a production and tumor
cell cytotoxicity mediated by murine peritoneal-derived macrophages. These
observations indicate that the biological effects of CsA and TGF-# on immune
functions are of a wider range than previously reported.
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